溃疡性结肠炎诊治现状及治疗进展
Current Status of Diagnosis and Treatment and Progress of Treatment of Ulcerative Colitis
摘要: 溃疡性结肠炎是一种影响结肠的慢性炎症性疾病，其发病率及患病率在世界范围呈上升趋势。由于溃疡性结肠炎的病因及机制尚不清楚，且缺乏确切的诊断方法，因此对于UC的诊断和治疗仍面临挑战。正确的诊断和病情评估影响着UC治疗方案的选择和患者的预后。UC的药物治疗包括5-氨基水杨酸、皮质类固醇、生物制剂和小分子药物等，带有新靶点药物的出现扩大了治疗选择范围，亦有部分患者需要接受手术治疗。为达到长期治疗目标，在标准治疗的基础上辅以饮食、运动及心理干预等补充替代疗法能更好的提高缓解率，从多个层面实现整体缓解。面对出现的新的治疗方法，需要对UC患者的病情评估后制定个性化方案，为患者建立更好的收益模式。
Abstract: Ulcerative colitis is a chronic inflammatory disease affecting the colon, and its incidence and prevalence are on the rise worldwide. The diagnosis and treatment of UC remains challenging because the etiology and mechanisms of ulcerative colitis are unknown and definitive diagnostic methods are lacking. Correct diagnosis and evaluation of the disease affect the choice of treatment and prognosis for UC, which is treated with 5-aminosalicylic acid, corticosteroids, biologics, and small molecules, with the emergence of new target drugs expanding the range of therapeutic choices, and with some patients requiring surgery. In order to achieve long-term treatment goals, complementary alternative therapies such as diet, exercise and psychological interventions on top of standard treatments can improve the remission rate and achieve overall remission on multiple levels. In the face of new therapeutic approaches, it is necessary to assess the condition of UC patients and develop individualized plans to establish a better pattern of benefits for the patient.
文章引用：郝家耀, 孟存英. 溃疡性结肠炎诊治现状及治疗进展[J]. 临床医学进展, 2024, 14(4): 1755-1761. https://doi.org/10.12677/acm.2024.1441221

参考文献

[1] Buie, M.J., Quan, J., Windsor, J.W., et al. (2023) Global Hospitalization Trends for Crohn’s Disease and Ulcerative Colitis in the 21st Century: A Systematic Review with Temporal Analyses. Clinical Gastroenterology and Hepatology, 21, 2211-2221. [Google Scholar] [CrossRef] [PubMed]
[2] Le Berre, C., Honap, S. and Peyrin-Biroulet, L. (2023) Ulcerative Colitis. The Lancet, 402, 571-584. [Google Scholar] [CrossRef] 
[3] Xu, L., He, B., Sun, Y. and Li, J. (2023) Incidence of Inflammatory Bowel Disease in Urban China: A Nationwide Population-Based Study. Clinical Gastroenterology and Hepatology.
[4] Satsangi, J., Silverberg, M.S., Vermeire, S. and Colombel, J.F. (2006) The Montreal Classification of Inflammatory Bowel Disease: Controversies, Consensus, and Implications. Gut, 55, 749-753. [Google Scholar] [CrossRef] [PubMed]
[5] 何美萍, 徐月. 蒙特利尔分型下溃疡性结肠炎急性期保留灌肠插管深度的探讨[J]. 中国中医急症, 2018, 27(4): 663-665.
[6] 宋孝美, 于劲, 史立伟, 等. 炎症性肠病内镜评分的临床应用及评价[J]. 中华炎性肠病杂志, 2023, 7(1): 2-6.
[7] Xie, T., Zhang, T., Ding, C., et al. (2018) Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Score (MES) in Guiding the Need for Colectomy in Patients with Acute Severe Colitis. Gastroenterology Report (Oxford), 6, 38-44. [Google Scholar] [CrossRef] [PubMed]
[8] Peyrin-Biroulet, L., Arenson, E., Rubin, D.T., et al. (2023) A Comparative Evaluation of the Measurement Properties of Three Histological Indices of Mucosal Healing in Ulcerative Colitis: Geboes Score, Robarts Histopathology Index and Nancy Index. Journal of Crohn’s and Colitis, 17, 1733-1743. [Google Scholar] [CrossRef] [PubMed]
[9] Feagan, B.G., Chande, N. and MacDonald, J.K. (2013) Are There Any Differences in the Efficacy and Safety of Different Formulations of Oral 5-ASA Used Forinduction and Maintenance of Remission in Ulcerative Colitis Evidence from Cochrane Reviews. Inflammatory Bowel Diseases, 19, 2031-2040. [Google Scholar] [CrossRef] 
[10] Kato, S., Ishibashi, A., Kani, K. and Yakabi, K. (2018) Optimized Management of Ulcerative Proctitis: When and How to Use Mesalazine Suppository. Digestion, 97, 59-63. [Google Scholar] [CrossRef] [PubMed]
[11] Choi, Y.S., Kim, W.J., Kim, J.K., Kim, D.S. and Lee, D.H. (2018) Efficacy of Topical 5-Aminosalicylate Monotherapy in Patients with Ulcerativeproctitis with Skip Inflammation. Journal of Gastroenterology and Hepatology, 33, 1200-1206. [Google Scholar] [CrossRef] [PubMed]
[12] 中华医学会消化病学分会炎症性肠病学组, 中国炎症性肠病诊疗质量控制评估中心. 中国溃疡性结肠炎诊治指南(2023年·西安) [J]. 中华炎性肠病杂志, 2024, 8(1): 33-58.
[13] Singh, S. (2023) Positioning Therapies for the Management of Inflammatory Bowel Disease. Nature Reviews Gastroenterology & Hepatology, 20, 411-412. [Google Scholar] [CrossRef] [PubMed]
[14] Lynch, R.W., Lowe, D., Protheroe, A., Driscoll, R., Rhodes, J.M. and Arnott, I.D.R. (2013) Outcomes of Rescue Therapy in Acute Severe Ulcerativecolitis: Data from the United Kingdom Inflammatory Bowel Diseaseaudit. Alimentary Pharmacology & Therapeutics, 38, 935-945. [Google Scholar] [CrossRef] [PubMed]
[15] Dai, N., Haidar, O., Askari, A. and Segal, J.P. (2022) Colectomy Rates in Ulcerativecolitis: A Systematic Review and Meta-Analysis. Digestive and Liver Disease, 55, 13-20. [Google Scholar] [CrossRef] [PubMed]
[16] Vavricka, S.R., Schoepfer, A., Scharl, M., et al. (2015) Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 21, 1982-1992. [Google Scholar] [CrossRef] 
[17] Fazio, V.W., Kiran, R.P., Remzi, F.H., et al. (2013) Ileal Pouch Anal Anastomosis: Analysis of Outcome and Quality of Life in 3707 Patients. Annals of Surgery, 257, 679-685. [Google Scholar] [CrossRef] 
[18] 蒋晓芸, 戎兰, 王悦之, 等. 炎症性肠病的肠外表现[J]. 中华消化杂志, 2007, 27(9): 628-629.
[19] Kilic, Y., Kamal, S., Jaffar, F., Sriranganathan, D., Quraishi, M.N. and Segal, J.P. (2024) Prevalence of Extraintestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Inflammatory Bowel Diseases, 30, 230-239. [Google Scholar] [CrossRef] [PubMed]
[20] Alizadeh, M., Motwani, K., Siaton, B.C., et al. (2023) Factors Associated with Extraintestinal Manifestations of Inflammatory Bowel Disease in SPARC-IBD. Inflammatory Bowel Diseases. [Google Scholar] [CrossRef] [PubMed]
[21] Barrie, A. and Regueiro, M. (2007) Biologic Therapy in the Management of Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 13, 1424-1429. [Google Scholar] [CrossRef] [PubMed]
[22] Greenstein, A.J., Janowitz, H.D. and Sachar, D.B. (1976) The Extra-Intestinal Complications of Crohn’s Disease and Ulcerative Colitis: A Study of 700 Patients. Medicine (Baltimore), 55, 401-412. [Google Scholar] [CrossRef] [PubMed]
[23] Tavarela Veloso, F. (2004) Review Article: Skin Complications Associated with Inflammatory Bowel Disease. Alimentary Pharmacology & Therapeutics, 20, 50-53. [Google Scholar] [CrossRef] [PubMed]
[24] Wenzel, J., Gerdsen, R., Phillipp-Dormston, W., Bieber, T. and Uerlich, M. (2002) Topical Treatment of Pyoderma Gangraenosum. Dermatology, 205, 221-223. [Google Scholar] [CrossRef] [PubMed]
[25] Brooklyn, T.N., Dunnill, M.G., Shetty, A., Bowden, J.J., Williams, J.D., Griffiths, C.E., Forbes, A., Greenwood, R. and Probert, C.S. (2006) Infliximab for the Treatment of Pyoderma Gangrenosum: A Randomised, Double Blind, Placebo Controlled Trial. Gut, 55, 505-509. [Google Scholar] [CrossRef] [PubMed]
[26] Hale, S. and Lightman, S. (2006) Anti-TNF Therapies in the Management of Acute and Chronic Uveitis. Cytokine, 33, 231-237. [Google Scholar] [CrossRef] [PubMed]
[27] Danese, S., Semeraro, S., Papa, A., Roberto, I., Scaldaferri, F., Fedeli, G., Gasbarrini, G. and Gasbarrini, A. (2005) Extraintestinal Manifestations in Inflammatory Bowel Disease. World Journal of Gastroenterology, 11, 7227-7236. [Google Scholar] [CrossRef] [PubMed]
[28] Loftus, E.V., Harewood, G.C., Loftus, C.G., Tremaine, W.J., Harmsen, W.S., Zinsmeister, A.R., Jewell, D.A. and Sandborn, W.J. (2005) PSC-IBD: A Unique Form of Inflammatory Bowel Disease Associated with Primary Sclerosing Cholangitis. Gut, 54, 91-96. [Google Scholar] [CrossRef] [PubMed]
[29] Khademi, Z., Pourreza, S., Amjadifar, A., Torkizadeh, M. and Amirkhizi, F. (2024) Dietary Patterns and Risk of Inflammatory Bowel Disease: A Systematic Review of Observational Studies. Inflammatory Bowel Diseases. [Google Scholar] [CrossRef] [PubMed]
[30] Chicco, F., Magrì, S., Cingolani, A., et al. (2021) Multidimensional Impact of Mediterranean Diet on IBD Patients. Inflammatory Bowel Diseases, 27, 1-9. [Google Scholar] [CrossRef] [PubMed]
[31] Chiba, M., Tsuji, T., Nakane, K., et al. (2020) High Remission Rate with Infliximab and Plant-Based Diet as First-Line (IPF) Therapy for Severe Ulcerative Colitis: Single-Group Trial. The Permanente Journal, 24, 1-10. [Google Scholar] [CrossRef] 
[32] Barberio, B., Zamani, M., Black, C.J., Savarino, E.V. and Ford, A.C. (2021) Prevalence of Symptoms of Anxiety and Depression in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. The Lancet Gastroenterology and Hepatology, 6, 359-370. [Google Scholar] [CrossRef] 
[33] Nigro, G., Angelini, G., Grosso, S.B., Caula, G. and Sategna-Guidetti, C. (2001) Psychiatric Predictors of Noncompliance in Inflammatory Bowel Disease: Psychiatry and Compliance. Journal of Clinical Gastroenterology, 32, 66-68. [Google Scholar] [CrossRef] [PubMed]
[34] Moreira, F.P., Cardoso Tde, A., Mondin, T.C., et al. (2015) The Effect of Proinflammatory Cytokines in Cognitive Behavioral Therapy. Journal of Neuroimmunology, 285, 143-146. [Google Scholar] [CrossRef] [PubMed]
[35] Sciberras, M., Karmiris, K., Nascimento, C., et al. (2022) Mental Health, Work Presenteeism, and Exercise in Inflammatory Bowel Disease. Journal of Crohn’s and Colitis, 16, 1197-1201. [Google Scholar] [CrossRef] [PubMed]
[36] Milo, F., Imondi, C., D’Amore, C., et al. (2024) Short-Term Psychodynamic Psychotherapy in Addition to Standard Medical Therapy Increases Clinical Remission in Adolescents and Young Adults with Inflammatory Bowel Disease: A Randomised Controlled Trial. Journal of Crohn’s and Colitis, 18, 256-263. [Google Scholar] [CrossRef] [PubMed]
[37] Zand, A., Van Deen, W.K., D’Haens, G.R., et al. (2015) Presenteeism in Inflammatory Bowel Diseases: A Hidden Problem with Significant Economic Impact. Inflammatory Bowel Diseases, 21, 1623-1630. [Google Scholar] [CrossRef] 
[38] Jones, P.D., Kappelman, M.D., Martin, C.F., et al. (2015) Exercise Decreases Risk of Future Active Disease in Patients with Inflammatory Bowel Disease in Remission. Inflammatory Bowel Diseases, 21, 1063-1071. [Google Scholar] [CrossRef] 
[39] 周颖, 柳惠未. 运动在炎症性肠病患者辅助治疗中的研究进展[J]. 中华炎性肠病杂志, 2023, 7(4): 346-350.

为你推荐